Mergers & Acquisitions ·
Sanara MedTech Inc. entered into a definitive Agreement and Plan of Merger with MiMedx Group, Inc., under which MiMedx…
SMTISanara MedTech Inc.
Sanara MedTech Inc. entered into a definitive Agreement and Plan of Merger with MiMedx Group, Inc., under which MiMedx will acquire Sanara in an all-stock and cash transaction. Upon closing, each share of Sanara common stock will be converted into $33.00 in cash plus 0.4735 shares of MiMedx common stock, representing a total consideration value of approximately $35.00 per share based on recent trading prices. The merger requires approval by Sanara's stockholders and customary regulatory clearances, including Hart-Scott-Rodino waiting periods. Specified stockholders holding approximately 38.9% of voting power have agreed to vote in favor of the transaction. If terminated under specific circumstances, Sanara must pay a $9,660,336 termination fee, while MiMedx owes $22,540,785 if it fails to consummate. This filing corrects an initial reporting error regarding these termination fee amounts. Sanara MedTech Inc. operates in the medical technology industry, specializing in the processing and distribution of amniotic membrane products for regenerative medicine.